- Home
- MCRB vs BCTX Comparison
MCRB vs BCTX Comparison
Compare MCRB & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRB | BCTX |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2M | 36.6M |
| IPO Year | 2015 | 2025 |
Fundamental Metrics
Financial Performance| Metric | MCRB | BCTX |
|---|---|---|
| Price | $2.12 | $3.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | 70.9K | ★ 84.8K |
| Earning Date | 11-04-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $789,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $2.60 |
| 52 Week High | $29.98 | $13.90 |
Technical Indicators
Market Signals| Indicator | MCRB | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 19.80 | 38.37 |
| Support Level | N/A | $3.35 |
| Resistance Level | $9.53 | $3.74 |
| Average True Range (ATR) | 0.21 | 0.21 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 13.73 | 9.08 |
Price Performance
Historical ComparisonAbout MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.